Fzata Awards 2024
-
"Finalist" at BIO International Start-up Stadium
-
Recipient of $7MM from NIH to study Visceral Pain 2024
-
A winner of the Global Health Innovation Challenge II
Intro Video 2 min.
Our MISSION
Expand safety, efficacy & access for therapeutic biologics leveraging BioPYM oral administration
Our oral biologics for gastrointestinal (GI) disorders will:
-
Improve patient safety with no systemic toxicities
-
Improve efficacy with biologics targeted directly to GI where disease occurs
-
Improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules
-
Improve patient compliance with no needles and no health-care administrated infusion
-
Improve chronic use outcomes given the high safety profile, no ADA, no systemic toxicity
The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) uses yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.
Fzata, Inc. 1450 S. Rolling Rd, Room 4.097, Halethorpe, Maryland 21227 USA
443.543.5040 info (type @) fzata.com